Literature DB >> 32016582

Risk Factors for Cardiac and Non-cardiac Causes of Death in Males with Duchenne Muscular Dystrophy.

Carol A Wittlieb-Weber1,2, Kenneth R Knecht3, Chet R Villa4, Chentel Cunningham5, Jennifer Conway5, Matthew J Bock6, Katheryn E Gambetta7, Ashwin K Lal8, Kurt R Schumacher9, Sabrina P Law10, Shriprasad R Deshpande11, Shawn C West12, Joshua M Friedland-Little13, Irene D Lytrivi10, Michael A McCulloch14, Ryan J Butts15, David R Weber16, Jonathan N Johnson17.   

Abstract

As survival and neuromuscular function in Duchenne muscular dystrophy (DMD) have improved with glucocorticoid (GC) therapy and ventilatory support, cardiac deaths are increasing. Little is known about risk factors for cardiac and non-cardiac causes of death in DMD. A multi-center retrospective cohort study of 408 males with DMD, followed from January 1, 2005 to December 31, 2015, was conducted to identify risk factors for death. Those dying of cardiac causes were compared to those dying of non-cardiac causes and to those alive at study end. There were 29 (7.1%) deaths at a median age of 19.5 (IQR: 16.9-24.6) years; 8 (27.6%) cardiac, and 21 non-cardiac. Those living were younger [14.9 (IQR: 11.0-19.1) years] than those dying of cardiac [18 (IQR 15.5-24) years, p = 0.03] and non-cardiac [19 (IQR: 16.5-23) years, p = 0.002] causes. GC use was lower for those dying of cardiac causes compared to those living [2/8 (25%) vs. 304/378 (80.4%), p = 0.001]. Last ejection fraction prior to death/study end was lower for those dying of cardiac causes compared to those living (37.5% ± 12.8 vs. 54.5% ± 10.8, p = 0.01) but not compared to those dying of non-cardiac causes (37.5% ± 12.8 vs. 41.2% ± 19.3, p = 0.58). In a large DMD cohort, approximately 30% of deaths were cardiac. Lack of GC use was associated with cardiac causes of death, while systolic dysfunction was associated with death from any cause. Further work is needed to ensure guideline adherence and to define optimal management of systolic dysfunction in males with DMD with hopes of extending survival.

Entities:  

Keywords:  Duchenne muscular dystrophy; Dystrophic cardiomyopathy; Heart failure; Sudden cardiac death

Mesh:

Year:  2020        PMID: 32016582      PMCID: PMC7328368          DOI: 10.1007/s00246-020-02309-y

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  25 in total

Review 1.  BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review.

Authors:  Pasqualina L Santaguida; Andrew C Don-Wauchope; Mark Oremus; Robert McKelvie; Usman Ali; Stephen A Hill; Cynthia Balion; Ronald A Booth; Judy A Brown; Amy Bustamam; Nazmul Sohel; Parminder Raina
Journal:  Heart Fail Rev       Date:  2014-08       Impact factor: 4.214

Review 2.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Susan D Apkon; Angela Blackwell; David Brumbaugh; Laura E Case; Paula R Clemens; Stasia Hadjiyannakis; Shree Pandya; Natalie Street; Jean Tomezsko; Kathryn R Wagner; Leanne M Ward; David R Weber
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

Review 3.  A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy.

Authors:  Jean K Mah; Lawrence Korngut; Jonathan Dykeman; Lundy Day; Tamara Pringsheim; Nathalie Jette
Journal:  Neuromuscul Disord       Date:  2014-03-22       Impact factor: 4.296

4.  Duchenne muscular dystrophy: survival by cardio-respiratory interventions.

Authors:  Yuka Ishikawa; Toshihiko Miura; Yukitoshi Ishikawa; Tomoyuki Aoyagi; Hitoko Ogata; Satoshi Hamada; Ryoji Minami
Journal:  Neuromuscul Disord       Date:  2010-12-08       Impact factor: 4.296

Review 5.  Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Benjamin A Alman; Susan D Apkon; Angela Blackwell; Laura E Case; Linda Cripe; Stasia Hadjiyannakis; Aaron K Olson; Daniel W Sheehan; Julie Bolen; David R Weber; Leanne M Ward
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

6.  Health profile of a cohort of adults with Duchenne muscular dystrophy.

Authors:  Shree Pandya; Katherine A James; Christina Westfield; Shiny Thomas; Deborah J Fox; Emma Ciafaloni; Richard T Moxley
Journal:  Muscle Nerve       Date:  2018-03-30       Impact factor: 3.217

7.  Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy.

Authors:  Brent J Barber; Jennifer G Andrews; Zhenqiang Lu; Nancy A West; F John Meaney; Elinora T Price; Ashley Gray; Daniel W Sheehan; Shree Pandya; Michele Yang; Christopher Cunniff
Journal:  J Pediatr       Date:  2013-07-15       Impact factor: 4.406

8.  Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy.

Authors:  Larry W Markham; Kathi Kinnett; Brenda L Wong; D Woodrow Benson; Linda H Cripe
Journal:  Neuromuscul Disord       Date:  2008-04-23       Impact factor: 4.296

9.  Predictors of Death in Adults With Duchenne Muscular Dystrophy-Associated Cardiomyopathy.

Authors:  Daniel Cheeran; Shaida Khan; Rohan Khera; Anish Bhatt; Sonia Garg; Justin L Grodin; Robert Morlend; Faris G Araj; Alpesh A Amin; Jennifer T Thibodeau; Sandeep Das; Mark H Drazner; Pradeep P A Mammen
Journal:  J Am Heart Assoc       Date:  2017-10-17       Impact factor: 5.501

10.  Survival in Duchenne muscular dystrophy.

Authors:  Susanne Rall; Tiemo Grimm
Journal:  Acta Myol       Date:  2012-10
View more
  6 in total

1.  Life Expectancy in Duchenne Muscular Dystrophy: Reproduced Individual Patient Data Meta-analysis.

Authors:  Jonathan Broomfield; Micki Hill; Michela Guglieri; Michael Crowther; Keith Abrams
Journal:  Neurology       Date:  2021-10-13       Impact factor: 9.910

2.  Selected clinical and demographic factors and all-cause mortality among individuals with Duchenne muscular dystrophy in the Muscular Dystrophy Surveillance, Tracking, and Research Network.

Authors:  Pangaja Paramsothy; Yinding Wang; Bo Cai; Kristin M Conway; Nicholas E Johnson; Shree Pandya; Emma Ciafaloni; Katherine D Mathews; Paul A Romitti; James F Howard; Catharine Riley
Journal:  Neuromuscul Disord       Date:  2022-04-30       Impact factor: 3.538

3.  Diversity of Dystrophin Gene Mutations and Disease Progression in a Contemporary Cohort of Duchenne Muscular Dystrophy.

Authors:  Katheryn E Gambetta; Michael A McCulloch; Ashwin K Lal; Kenneth Knecht; Ryan J Butts; Chet R Villa; Jonathan N Johnson; Jennifer Conway; Matthew J Bock; Kurt R Schumacher; Sabrina P Law; Joshua M Friedland-Little; Shriprasad R Deshpande; Shawn C West; Irene D Lytrivi; Carol A Wittlieb-Weber
Journal:  Pediatr Cardiol       Date:  2022-01-22       Impact factor: 1.655

4.  Duchenne muscular dystrophy patients: troponin leak in asymptomatic and implications for drug toxicity studies.

Authors:  Larry W Markham; Jonathan H Soslow; Aryaz Sheybani; Kim Crum; Frank J Raucci; William B Burnette
Journal:  Pediatr Res       Date:  2021-08-24       Impact factor: 3.756

5.  Health Care Use of Cardiac Specialty Care in Children With Muscular Dystrophy in the United States.

Authors:  Erika J Mejia; Kimberly Y Lin; Oluwatimilehin Okunowo; Katherine A Iacobellis; Susan E Matesanz; John F Brandsema; Carol A Wittlieb-Weber; Hannah Katcoff; Heather Griffis; Jonathan B Edelson
Journal:  J Am Heart Assoc       Date:  2022-04-12       Impact factor: 6.106

Review 6.  The multifaceted view of heart problem in Duchenne muscular dystrophy.

Authors:  Urszula Florczyk-Soluch; Katarzyna Polak; Józef Dulak
Journal:  Cell Mol Life Sci       Date:  2021-06-06       Impact factor: 9.261

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.